Trustedge Capital Limited has submitted its quarterly compliance certificate to BSE Limited, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018. The certificate pertains to the quarter ended March 31, 2026, and was filed on April 07, 2026.

Regulatory Filing Details

The compliance certificate was submitted pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. Company Secretary and Compliance Officer Pinkal Mehta signed the submission letter, confirming the company's adherence to regulatory requirements.

Registrar Confirmation

Bigshare Services Private Limited, serving as the company's Registrar and Share Transfer Agent (RTA), provided the confirmation certificate. The RTA confirmed that all securities received from depository participants for dematerialization up to March 31, 2026 were properly processed and confirmed to the depositories.

Key Compliance Confirmations

The certificate from Bigshare Services confirms several critical compliance aspects:

• Securities received for dematerialization were accepted or rejected as appropriate
• All securities in the certificates have been listed on relevant stock exchanges
• Security certificates received for dematerialization were mutilated and cancelled after proper verification
• Depository names were substituted in the register of members within the required 15-day timeframe

Company Information

Trustedge Capital Limited, formerly known as Adinath Exim Resources Limited, operates from its registered office in Ahmedabad, Gujarat. The company maintains its corporate presence at Office No. 308, 3rd Floor, Block-B, Navratna Corporate Park, Bodakdev, Ahmedabad.

This quarterly filing demonstrates the company's commitment to maintaining regulatory compliance and transparency in its depository participant operations, ensuring proper handling of securities dematerialization processes as mandated by SEBI regulations.

Trustedge Capital Limited has submitted its monitoring agency report for the quarter ended December 31, 2025, demonstrating compliant utilization of its rights issue proceeds. The report, prepared by CARE Ratings Limited as the monitoring agency, confirms no material deviations from the original fund utilization plan disclosed in the offer document.

Rights Issue Details and Fund Deployment

The company successfully completed its rights issue during October 9-16, 2025, raising Rs. 26.99 crore through equity shares. The monitoring report shows substantial progress in fund utilization across all designated objects during the quarter.

Capital Base Augmentation and Business Expansion

The primary objective of augmenting the capital base received Rs. 19.25 crore utilization through loan disbursals. The company provided a declaration confirming no disbursals were made to related parties or group companies, maintaining compliance with regulatory requirements.

Under general corporate purposes, the company allocated Rs. 5.00 crore specifically for business expansion through loan disbursals, as approved by the Rights Issue Committee. This allocation aligns with the offer document provisions allowing board-approved purposes subject to applicable laws.

General Corporate Purpose Breakdown

The detailed utilization of Rs. 5.69 crore under general corporate purposes includes:

Unutilized Funds Management

The remaining Rs. 1.67 crore has been prudently deployed in financial instruments to generate returns while maintaining liquidity. The company placed Rs. 1.70 crore in a fixed deposit with Axis Bank earning 5.80% return, maturing on January 27, 2026. Additionally, Rs. 0.05 crore is maintained in the monitoring account with Axis Bank.

Regulatory Compliance and Timeline Adherence

CARE Ratings Limited confirmed no delays in implementation of stated objects, with all activities progressing as per the FY25-26 timeline mentioned in the offer document. Issue expenses were completed by November 2025, while capital augmentation and general corporate purposes remain ongoing as planned.

The monitoring agency noted that actual issue expenses of Rs. 0.43 crore exceeded the estimated Rs. 0.38 crore, with the excess Rs. 0.05 crore adjusted against general corporate purposes as permitted under the offer document terms. This adjustment represents standard practice and does not constitute a deviation from the disclosed utilization plan.